These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

719 related articles for article (PubMed ID: 28171710)

  • 1. Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
    Armstrong AJ; Saad F; Phung D; Dmuchowski C; Shore ND; Fizazi K; Hirmand M; Forer D; Scher HI; Bono J
    Cancer; 2017 Jun; 123(12):2303-2311. PubMed ID: 28171710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial.
    Saad F; de Bono J; Shore N; Fizazi K; Loriot Y; Hirmand M; Franks B; Haas GP; Scher HI
    Eur Urol; 2015 Feb; 67(2):223-30. PubMed ID: 25171902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
    Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J
    Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
    Armstrong AJ; Lin P; Higano CS; Iversen P; Sternberg CN; Tombal B; Phung D; Parli T; Krivoshik A; Beer TM
    Eur Urol Oncol; 2019 Nov; 2(6):677-684. PubMed ID: 31274110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
    Zhang T; Dhawan MS; Healy P; George DJ; Harrison MR; Oldan J; Chin B; Armstrong AJ
    Clin Genitourin Cancer; 2015 Aug; 13(4):392-399. PubMed ID: 25708161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
    Hussain M; Fizazi K; Saad F; Rathenborg P; Shore N; Ferreira U; Ivashchenko P; Demirhan E; Modelska K; Phung D; Krivoshik A; Sternberg CN
    N Engl J Med; 2018 Jun; 378(26):2465-2474. PubMed ID: 29949494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
    Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
    Nadal R; Zhang Z; Rahman H; Schweizer MT; Denmeade SR; Paller CJ; Carducci MA; Eisenberger MA; Antonarakis ES
    Prostate; 2014 Nov; 74(15):1560-8. PubMed ID: 25176007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
    Loriot Y; Fizazi K; de Bono JS; Forer D; Hirmand M; Scher HI
    Cancer; 2017 Jan; 123(2):253-262. PubMed ID: 27648814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.
    Sternberg CN; de Bono JS; Chi KN; Fizazi K; Mulders P; Cerbone L; Hirmand M; Forer D; Scher HI
    Ann Oncol; 2014 Feb; 25(2):429-34. PubMed ID: 24478320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer.
    Kato H; Furuya Y; Miyazawa Y; Miyao T; Syuto T; Nomura M; Sekine Y; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
    Anticancer Res; 2016 Nov; 36(11):6141-6149. PubMed ID: 27793943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
    Suzman DL; Luber B; Schweizer MT; Nadal R; Antonarakis ES
    Prostate; 2014 Sep; 74(13):1278-85. PubMed ID: 25053178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients.
    Kim CS; Theeuwes A; Kwon DD; Choi YD; Chung BH; Lee HM; Lee KH; Lee SE
    Investig Clin Urol; 2016 May; 57(3):174-83. PubMed ID: 27195316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide.
    Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
    Urol Oncol; 2017 Jun; 35(6):432-437. PubMed ID: 28188090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
    Higano CS; Beer TM; Taplin ME; Efstathiou E; Hirmand M; Forer D; Scher HI
    Eur Urol; 2015 Nov; 68(5):795-801. PubMed ID: 25698064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.
    Thomsen FB; Røder MA; Rathenborg P; Brasso K; Borre M; Iversen P
    Scand J Urol; 2014 Jun; 48(3):268-75. PubMed ID: 24255983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer.
    Kim CS; Choi YD; Lee SE; Lee HM; Ueda T; Yonese J; Fukagai T; Chiong E; Lau W; Abhyankar S; Theeuwes A; Tombal B; Beer TM; Kimura G
    Medicine (Baltimore); 2017 Jul; 96(27):e7223. PubMed ID: 28682871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide.
    Miyake H; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
    Med Oncol; 2017 Nov; 34(12):200. PubMed ID: 29164346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
    Conteduca V; Jayaram A; Romero-Laorden N; Wetterskog D; Salvi S; Gurioli G; Scarpi E; Castro E; Marin-Aguilera M; Lolli C; Schepisi G; Maugeri A; Wingate A; Farolfi A; Casadio V; Medina A; Puente J; Vidal MJM; Morales-Barrera R; Villa-Guzmán JC; Hernando S; Rodriguez-Vida A; González-Del-Alba A; Mellado B; Gonzalez-Billalabeitia E; Olmos D; Attard G; De Giorgi U
    Eur Urol; 2019 Mar; 75(3):368-373. PubMed ID: 30773204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.